DTaPIPVHiB

DTaP-IPV-Hib is a pediatric pentavalent vaccine that combines components to protect against five diseases: diphtheria, tetanus, pertussis (acellular), poliomyelitis (inactivated polio vaccine), and Haemophilus influenzae type b (Hib). By including booster and primary series antigens in a single shot, it helps simplify immunization schedules and reduces the number of injections a child receives.

The vaccine contains three parts from the DTaP component, providing diphtheria and tetanus toxoids and acellular pertussis antigens, along with an inactivated poliovirus component and a Hib Hib polysaccharide conjugate component. It is administered by intramuscular injection, typically into the anterolateral thigh in infants and into the deltoid muscle in older children.

Immunization schedules vary by country but commonly involve a primary series given at around 2, 4, and 6 months of age, followed by booster doses at about 12–18 months and again during early school age in some programs. The vaccine may be co-administered with other routine childhood vaccines during well-child visits.

Common adverse events are usually mild and may include redness, swelling, or pain at the injection site and fever. Serious adverse events are rare. As with other vaccines, there are contraindications for individuals with a severe allergic reaction to a previous dose or to any vaccine component; moderate or severe illness may lead to postponement of vaccination.

DTaP-IPV-Hib is used within national immunization programs to provide broad protection against these diseases and to reduce the incidence of invasive Hib disease, diphtheria, tetanus, poliomyelitis, and pertussis in children.